Journal of Chromatography, 146 (1978) 350-353 Biomedical Applications © Elsevier Scientific Publishing Company, Amsterdam - Printed in The Netherlands CHROMBIO. 184

telestrates

Note

Determination of cytosine arabinoside in human plasma by high-pressure liquid chromatography

ROSS W. BURY* and PETER J. KEARY

Department of Medicine (St. Vincent's Hospital), University of Melbourne, Fitzroy, Victoria 3065 (Australia)

(Received March 13th, 1978)

Cytosine arabinoside $(1-\beta$ -D-arabinofuranosyl-cytosine; ara-C) is a pyrimidine analogue with significant anti-tumour activity and has been reported to be therapeutically effective in the treatment of acute myeloblastic leukaemia and other haematological malignancies [1-4].

The anti-metabolite properties of the drug apparently result from selective inhibition of DNA polymerase and incorporation into DNA (or RNA) following the formation of arabinosyl-CTP [5]. However, ara-C is not effective in all treated patients and Baguley and Falkenhaug [6] found that there was a significant correlation between failure of treatment and rapid clearance of the drug from the plasma. If an effective blood concentration is the sole determinant of efficacy, kinetic data could be used to establish the most appropriate dosage schedules. Nevertheless, the availability of active arabinosyl-CTP at tumour sites in appropriate concentration will ultimately determine efficacy and the relationship of this to ara-C blood concentrations needs to be explored.

Previous analytical methods for ara-C in blood have involved radioactive drug administration and subsequent measurement of radioactivity [6, 7], biological assay involving tissue culture [6, 8] or paper chromatography [7, 9]. The methods are complex and most are relatively insensitive. Wan et al. [7] reported that high-pressure liquid chromatography (HPLC) may prove useful in measurement of ara-C but provided little detail of methodology and other characteristics of their assay. The use of a rapid, simple and sensitive HPLC procedure for ara-C is now described in which plasma protein is removed by precipitation and a buffered aliquot of supernatant is injected directly into the chromatographic system.

^{*}To whom correspondence should be addressed.

METHODS AND MATERIALS

Blood specimens (10 ml) were collected in heparinized tubes containing 100 μ g tetrahydrouridine (THU), which prevents deamination of ara-C [5]. These were immediately stored at 4°. Plasma samples (2 ml) were pipetted into tubes containing 100 μ l 4 M trichloroacetic acid. After mixing for 20 sec on a vortex mixer, these were centrifuged for 20 min at 0° to separate the precipitated protein. A 1-ml volume of supernatant was immediately transferred to another tube and 20 μ l 5 M ammonium formate buffer (pH 7.0) was added to achieve a final pH of approx. 3.5. Aliquots of 100 μ l were then injected into the chromatograph.

Analyses were performed on a cation-exchange column (Whatman Partisil PXS 10/25 SCX; 250×4.6 mm) using 0.01 *M* ammonium formate (pH 4.8) at a constant flow-rate of 1.0 ml/min as the mobile phase. A single-piston high-pressure pump (Altex model 110), a sample injection valve containing a 100- μ l loop (Chromatronix) and a fixed-wavelength ultraviolet detector with a 20- μ l flow cell (Altex model 150) formed the basis of the chromatograph.

Absorbance of the effluent from the column at 254 nm was monitored at a sensitivity of 0.005 a.u.f.s. Peak heights were used for quantitation of the assay.

To prevent contamination of the ion-exchange column by plasma constituents remaining after the protein removal step, a pre-column (50 \times 4.6 mm) containing reversed-phase packing (Partisil ODS, 10 μ m; Reeve Angel) was incorporated into the system. Ara-C was not appreciably retained by the precolumn. Significant increases in perfusion pressure necessitating a change of pre-column (at 3000 p.s.i.) did not occur until about 100 samples had been passed through the system.

All chemicals used were analytical grade and water was doubly distilled. Ara-C and THU were kindly donated by Upjohn (Kalamazoo, Mich., U.S.A.). Calibration curves were derived from pooled blood bank plasma.

RESULTS AND DISCUSSION

Typical chromatograms of plasma samples (Fig. 1) show that control samples are free from contaminating peaks. Ara-C was eluted in 11 min. The major metabolite of ara-C, 1- β -D-arabinofuranosyl uracil (ara-U) was eluted with the large initial mass of endogenous material. All calibration curves for ara-C passed through the origin and were linear from the detection limit of 20 ng/ml plasma to the maximum concentration used (1 μ g/ml). Concentration of ara-C in the plasma as a result of the precipitation of plasma protein led to a high recovery of the drug throughout the concentration range listed above (mean recovery 109.5%; S.E.M. 0.7%; n=10) in comparison to standard aqueous solutions of ara-C. The coefficient of variation for the analysis was determined to be 1.7% (n=10) at a concentration of 200 ng/ml.

Blood samples from six hospitalised leukaemic patients receiving constant intravenous infusions of ara-C over 7 days were taken twice between days 2 and 7 to determine the plasma levels likely to be obtained in a steady-state situation (Table I). There was no apparent correlation between the dose of ara-C admin-

NAL STANK STREET

n sesti seekeens s Soossa sekkeessa

n (1997) - Angli (1997) - Angli (1997) 1997 - Angli Angli (1997) - Angli (1997)

그는 글을 가지?

5100

Bibby printing the first of the second of the second formation of the second formation to the second set $n \in \mathbb{N}^{-1}$ for any set $n \in \mathbb{N}^{+1}$ for any set $n \in \mathbb{N}^{+1}$ for any set $n \in \mathbb{N}^{+1}$ for $n \in \mathbb{N}^{+1}$ and $n \in \mathbb{N}^{+1}$ for $n \in \mathbb{N}^{+1}$




Fig. 1. Typical chromatograms for ara-C in deproteinized plasma. The ordinate represents absorbance units (AU). The arrows indicate the peaks eluting as ara-C. a, blank; b, 50 ng/ml ara-C; c, 500 ng/ml ara-C.

+

TABLE I

STEADY-STATE PLASMA CONCENTRATIONS OF ARA-C IN SIX PATIENTS WITH ACUTE MYELOID LEUKEMIA

Patients received constant intravenous infusion of ara-C for 7 days. Blood samples from each patient were taken on separate days. Each level represents the mean of duplicate estimations.

Patient	Surface area (m²)	Dose (mg/m²/d́ay)	Ara-C plasma concentrations in steady state (ng/ml)
P.C			041 009
E.C.	1.9	70	241, 223 168, 170 88, 79
	1.6		100, 170
R.B.	1.6	70 70	88, 79
L.P.	1.4	70	- 76, 80 (1997) - 1997 (1997
R.T.	1.6	un 130 - L'arter Articel	5 105, 114 - Sectors and the existence of the sectors
B.J.	1.9	150	153,135 (Constant), and in the second second p
	the second s		

istered daily and the plasma concentration attained in these patients. This is probably a reflection of pharmacokinetic variability and emphasizes the difficulties in establishing appropriate dosage schedules. Routine measurement of ara-C in plasma may prove useful in this regard.

na march - 7, sa ca chuna an sala bhliachannan na A

and the state of the

antes sure that see a state to see and another

REFERENCES

1 M.Y. Chu and G.A. Fischer, Biochem. Pharmacol., 17 (1968) 753.

352

- 2 R.R. Ellison, J.F. Holland, M. Weil, C. Jacquillet, M. Boiron, J. Bernard, A. Sawitsky, F. Rosner, B. Gussaf, R. Silver, A. Karanas, J. Cuttner, C.L. Spurr, D.M. Hayes, S. Blom, L.A. Leone, F. Hanrani, R. Kyle, J.L. Hutchinson, R. Forcier and J.H. Moon, Blood, 32 (1968) 507. 3 B. Goodell, B. Leventhal and E. Henderson, Clin. Pharmacol. Ther., 12 (1971) 599.
- 4 E.S. Henderson, Seminars Haematol., 6 (1969) 271.
- 5 S.S. Cohen, Cancer, 40 (1977) 509.
- 6 B.C. Baguley and E.M. Falkenhaug, Cancer Chemother. Reports, 55 (1971) 291.
- 7 S.H. Wan, D.H. Huffman, D.L. Azarnoff, B. Hoogstraten and W.E. Larsen, Cancer Res., 34 (1974) 392.
- 8 R. van Prooijen, E. van der Kleijn and C. Haanen, Clin. Pharmacol. Ther., 21 (1977) 744.
- 9 D.H.W. Ho, N.S. Brown, J. Benvenuto, K.B. McCredie, D. Buckels and E.J. Freireich, Clin. Pharmacol. Exp. Ther., 22 (1977) 371.

a substant en al esta en en entre entre entre en entre service de la service en al substant de la service. A service de 13 de la constant en altre de Marine Marine (

et en el proper presente de la construcción de la construcción de la construcción de la construcción de la cons

en l'herrer e energe en propert es l'optimis de l'herre o comme de la second

ensetti en terre en la la sessión de set such an en el terre de ser en el terre en el terre en el terre en el t n de la segunda de la calega de l e a contra de la constanción de la constançación de casa de la

a general contact care a care care contage of the total care of

a falgen i del y ligen en tradices el menor de la construction en fel a seconda de la face en en f

in a state of the second state and the second state of

(主) 出来 (14)

eners als les écologies de la composition de la

推动推动,现在分子上,这些时间的人物了这个方面。 化乙基甲基乙基甲基乙基 ny. Ny faritr'ora dia mampina mandritry ny tanàna mandritry ny taona 2008–2014. Ilay kaominina dia kaominina dia kao

นที่มี สารณร แต่มี แต่งๆ แม้มาตารไปประวาทนับใหญ่นี้ แต่ง แต่มีก็การแบบ บบไป และสำนักที่ พระ แต่ง " a Characteristica a final cash success on a start to encoder a result

energe fan dien weiterik ateas as die geste stiel die die beste die beste in die gaar in die die s aparatin Melation a restantivos acadas, portas, constructivos de la Salis incluy anter Lengente leven anté é que no emplégie : desti le nequere : le que banda e de and any interprete any later for the factor and the state of a second state of a second second second second s randia tan gibigta na anta wati mani mangana majajarin katanati dala anta na manti Malifer antaki wilan bala -และวิธารณ์ที่เพื่อสารว่าได้ส